

## Title: The Treatment of Colorectal Cancer in the Era of Molecular Characterization



**Speaker**

### **Josep Tabernero, M.D.**

Head of the Medical Oncology Department at the Vall d'Hebron University Hospital, Spain



**Chairman**

### **Yuko Kitagawa, MD, Ph.D.**

Professor, Department of Surgery, Graduate School of Medicine, Keio University, Japan

### **Josep Tabernero, M.D.**

Josep Tabernero received his medical degree from the Universitat Autònoma de Barcelona, Spain. Afterwards, he completed his specialist training in medical oncology and has had appointments in Barcelona.

Dr. Tabernero is currently the Head of the Medical Oncology Department at the Vall d'Hebron University Hospital in Barcelona, Spain. He is also the head of the Gastrointestinal Tumors and Phase I Unit and is actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies and related translational research, with a special focus on EGFR-family inhibitors and IGFR-PI3K-Akt-mTOR pathway inhibitors, and also in phase II and III studies with new chemotherapy agents in gastrointestinal tumors.

In addition, Dr. Tabernero is a member of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO), and different Editorial Boards including the *Journal of Clinical Oncology*, *Clinical Cancer Research*, *Clinical Colorectal Cancer* and *Annals of Oncology*. He has (co)authored approximately 150 peer-reviewed papers. He has also been member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.

**IAAO2012 Title of the Talk:**

**The Treatment of Colorectal Cancer in the Era of Molecular  
Characterization**